biotech
biotech Articles
MyoKardia shares hit an all-time high early on Monday after it was announced that Bristol-Myers Squibb would be acquiring the company.
Published:
President Trump and the First Lady have tested positive for COVID-19. That begs the question, now more than ever, of where we stand with a coronavirus vaccine.
Published:
Solid Biosciences shares more than doubled on Thursday after the company announced a key update from the FDA.
Published:
Moderna and Regeneron Pharmaceuticals each announced positive news late on Tuesday about their respective COVID-19 vaccine trials.
Published:
Aptorum shares absolutely exploded on Tuesday after the company announced that it would be launching a subsidiary focused on novel technologies targeting infectious diseases.
Published:
Genfit SA (NASDAQ: GNFT) shot up on Monday after the company announced an agreement with Lab Corporation of America Holdings (NYSE: LH). This agreement is ultimately for Genfit’s technology to...
Published:
Eiger BioPharmaceuticals has announced disappointing results from a study of Peginterferon Lambda-1a (Lambda) in outpatients with mild and uncomplicated COVID-19.
Published:
Aquestive Therapeutics said that it had received a negative response from the FDA concerning its treatment for the management of seizure clusters.
Published:
Things aren’t looking up for Inovio Pharmaceuticals, after the FDA notified the company that it was placing a partial hold on its COVID-19 vaccine study.
Published:
The September 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
Published:
Credit Suisse has set an Outperform rating and $290 price target on Amgen shares. That target implies more than 20% upside to the stock's recent trading price.
Published:
Some small-cap companies will screen as having deep value, but many value stocks are deemed to be "cheap" because they lack any new catalysts and opportunities.
Published:
AC Immune stock was absolutely crushed on Wednesday after the firm announced disappointing results from its midstage Alzheimer’s disease study.
Published:
MediciNova has announced progress in its COVID-19 vaccine prototype, which stands out from the rest as it is administered intranasally.
Published:
The race for the COVID-19 vaccine is still very much on, and Johnson & Johnson just announced the launch of a Phase 3 trial.
Published: